Expression of ZNF148 in different developing stages of colorectal cancer and its prognostic value: A large Chinese study based on tissue microarray

Cancer

Volumn 119, Issue 12, 2013, Pages 2212-2222

  Gao, Xian Hua ^a   Liu, Qi Zhi ^a   Chang, Wenjun ^b   Xu, Xiao Dong ^a   Du, Yan ^b   Han, Yifang ^b   Liu, Yan ^b   Yu, Zhi Qi ^a   Zuo, Zhi Gui ^a   Xing, Jun Jie ^a   Cao, Guangwen ^b   Fu, Chuan Gang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

colon neoplasms; colorectal neoplasms; prognosis; rectal neoplasms; zinc finger protein 148 (ZNF148)

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 148;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR LOCALIZATION;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CA-19-9 ANTIGEN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTESTINAL MUCOSA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; REFERENCE VALUES; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84878568456     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28052     Document Type: Article

References (25)

1. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM,. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer. 2003; 88: 803-807.
2. Murata K, Miyoshi E, Kameyama M, et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res. 2000; 6: 1772-1777.
3. Zhang CZ, Chen GG, Lai PB,. Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim Biophys Acta. 2010; 1806: 36-41.
4. Chen GG, Chan UP, Bai LC, et al. ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest. Cancer Lett. 2009; 283: 52-58.
5. Thimmarayappa J, Sun J, Schultz LE, et al. Inhibition of growth hormone receptor gene expression by saturated fatty acids: role of Kruppel-like zinc finger factor, ZBP-89. Mol Endocrinol. 2006; 20: 2747-2760.
6. Remington MC, Tarle SA, Simon B, Merchant JL,. ZBP-89, a Kruppel-type zinc finger protein, inhibits cell proliferation. Biochem Biophys Res Commun. 1997; 237: 230-234.
7. Bai L, Merchant JL,. ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol. 2001; 21: 4670-4683.
8. Merchant JL, Iyer GR, Taylor BR, et al. ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol Cell Biol. 1996; 16: 6644-6653.
9. Law DJ, Tarle SA, Merchant JL,. The human ZBP-89 homolog, located at chromosome 3q21, represses gastrin gene expression. Mamm Genome. 1998; 9: 165-167.
10. Bai L, Logsdon C, Merchant JL,. Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer. Int J Gastrointest Cancer. 2002; 31: 79-88.
11. Bai L, Merchant JL,. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J Biol Chem. 2000; 275: 30725-30733.
12. Law DJ, Labut EM, Merchant JL,. Intestinal overexpression of ZNF148 suppresses ApcMin/+ neoplasia. Mamm Genome. 2006; 17: 999-1004.
13. Bandres E, Malumbres R, Cubedo E, et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep. 2007; 17: 1089-1094.
14. Bai L, Kao JY, Law DJ, Merchant JL,. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology. 2006; 131: 841-852.
15. Bai L, Merchant JL,. ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate. Biochem Biophys Res Commun. 2007; 359: 817-821.
16. Knut and Alice Wallenberg Foundation. Assays and Annotation. The Human Protein Atlas. http://www.proteinatlas.org/about/assays+annotation. Accessed April 16, 2012.
17. Siavoshian S, Segain JP, Kornprobst M, et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut. 2000; 46: 507-514.
18. Taniuchi T, Mortensen ER, Ferguson A, Greenson J, Merchant JL,. Overexpression of ZBP-89, a zinc finger DNA binding protein, in gastric cancer. Biochem Biophys Res Commun. 1997; 233: 154-160.
19. Zhang CZ, Cao Y, Yun JP, Chen GG, Lai PB,. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma. Histopathology. 2012; 60: 1114-1124.
20. Yamashita H, Toyama T, Nishio M, et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 2006; 8: R48.
21. Lan YT, Chang SC, Li AF, et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis. 2007; 22: 499-506.
22. Fu CG, Tominaga O, Nagawa H, et al. Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum. 1998; 41: 68-74.
23. Chen GG, Merchant JL, Lai PB, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol. 2003; 162: 1823-1829.
24. Khouja MH, Baekelandt M, Sarab A, Nesland JM, Holm R,. Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett. 2010; 1: 827-831.
25. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J,. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer. 2001; 93: 346-352.